Table 5 Summary of clinical findings from indistinguishable infections
From: Viral reactivations and co-infections in COVID-19 patients: a systematic review
| Â | EBV | CMV | VZV | B19 | Total (%) |
|---|---|---|---|---|---|
Number of cases | 46 | 3 | 1 | 1 | 51 (100.00) |
Sex | |||||
 Female | 1 | 3 |  | 1 | 5 (83.33) |
 Male |  |  | 1 |  | 1 (16.67) |
Total | Â | Â | Â | Â | 6 (100.00) |
COVID | Â | Â | Â | Â | Â |
 Severe/Critical | 7 |  |  |  | 7 (100.00) |
Total | 7 | 0 | 0 | 0 | 7 (100.00) |
Comorbidities/medical history | |||||
 Chickenpox |  |  | 1 | 1 | 2 (50.00) |
 Pneumonia |  | 1 |  | 1 | 2 (50.00) |
Total | 0 | 1 | 1 | 2 | 4 (100.00) |
Clinical manifestations | |||||
 Symptomatic | |||||
  Diarrhea |  |  | 1 |  | 1 (25.00) |
  Rash | 1 |  |  | 1 | 2 (50.00) |
  Skin lesions |  |  | 1 |  | 1 (25.00) |
  Total | 1 | 0 | 2 | 1 | 4 (100.00) |
 Complications | |||||
  Neuralgia |  |  | 1 |  | 1 (50.00) |
  Rectal ulcer |  | 1 |  |  | 1 (50.00) |
Total | 0 | 1 | 1 | 0 | 2 (100.00) |
Laboratory findings | |||||
 Elevated ALT level | 1 |  |  | 1 | 2 (28.57) |
 Elevated AST level |  |  |  | 1 | 1 (14.29) |
 Elevated D-dimer level | 1 |  |  | 1 | 2 (28.57) |
 Elevated LDH level | 1 |  |  | 1 | 2 (28.57) |
Total | 3 | 0 | 0 | 4 | 7 (100.00) |
Pharmacological interventions | |||||
 Acyclovir |  |  | 1 |  | 1 (33.33) |
 Pregabalin |  |  | 1 |  | 1 (33.33) |
 Valganciclovir |  | 1 |  |  | 1 (33.33) |
Total | 0 | 1 | 2 | 0 | 3 (100.00) |
Procedures | |||||
 ECMO |  |  | 1 |  | 1 (11.11) |
 Oxygen support | 7 | 1 |  |  | 8 (88.99) |
Total | 7 | 1 | 1 | 0 | 9 |